LUC00128I2 - - Google Patents

Download PDF

Info

Publication number
LUC00128I2
LUC00128I2 LU00128C LUC00128C LUC00128I2 LU C00128 I2 LUC00128 I2 LU C00128I2 LU 00128 C LU00128 C LU 00128C LU C00128 C LUC00128 C LU C00128C LU C00128 I2 LUC00128 I2 LU C00128I2
Authority
LU
Luxembourg
Application number
LU00128C
Original Assignee
Genmab As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39156080&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LUC00128(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Genmab As filed Critical Genmab As
Publication of LUC00128I2 publication Critical patent/LUC00128I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/69—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biomedical Technology (AREA)
  • Oncology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
LU00128C 2006-09-26 2019-10-02 LUC00128I2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US84732906P 2006-09-26 2006-09-26
DKPA200601232 2006-09-26

Publications (1)

Publication Number Publication Date
LUC00128I2 true LUC00128I2 (fr) 2024-05-22

Family

ID=39156080

Family Applications (4)

Application Number Title Priority Date Filing Date
LU00128C LUC00128I2 (fr) 2006-09-26 2019-10-02
LU00129C LUC00129I2 (fr) 2006-09-26 2019-10-02
LU00130C LUC00130I2 (fr) 2006-09-26 2019-10-02
LU50004C LUC50004I2 (fr) 2006-09-26 2025-04-15

Family Applications After (3)

Application Number Title Priority Date Filing Date
LU00129C LUC00129I2 (fr) 2006-09-26 2019-10-02
LU00130C LUC00130I2 (fr) 2006-09-26 2019-10-02
LU50004C LUC50004I2 (fr) 2006-09-26 2025-04-15

Country Status (24)

Country Link
US (4) US9040050B2 (fr)
EP (3) EP3753576A1 (fr)
JP (7) JP5476122B2 (fr)
AU (2) AU2007302448C1 (fr)
CA (1) CA2664740C (fr)
CY (8) CY1121813T1 (fr)
DK (1) DK2081595T3 (fr)
EA (1) EA034877B1 (fr)
ES (1) ES2732278T3 (fr)
FI (1) FIC20250018I1 (fr)
FR (7) FR19C1057I1 (fr)
HR (1) HRP20191115T1 (fr)
HU (7) HUE044136T2 (fr)
IL (2) IL197727A (fr)
LT (8) LT2081595T (fr)
LU (4) LUC00128I2 (fr)
ME (1) ME03503B (fr)
NZ (1) NZ576122A (fr)
PL (1) PL2081595T3 (fr)
PT (1) PT2081595T (fr)
RS (1) RS59005B1 (fr)
SI (1) SI2081595T1 (fr)
TR (1) TR201910145T4 (fr)
WO (1) WO2008037257A2 (fr)

Families Citing this family (77)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2551282A3 (fr) * 2005-03-23 2013-02-13 Genmab A/S Anticorps diriges contre CD38 pour le traitement du myelome multiple
PL2081595T3 (pl) * 2006-09-26 2019-11-29 Genmab As Anty-cd38 wraz z kortykosteroidami wraz ze środkiem chemioterapeutycznym niebędącym kortykosteroidem, do leczenia guzów nowotworowych
EP2191841A1 (fr) * 2008-11-28 2010-06-02 Sanofi-Aventis Combinaisons antitumorales contenant des anticorps reconnaissant spécifiquement les CD38 et vincristine
EP2191840A1 (fr) * 2008-11-28 2010-06-02 Sanofi-Aventis Combinaisons antitumorales contenant des anticorps reconnaissant spécifiquement les CD38 et melphalan
EP2191842A1 (fr) * 2008-11-28 2010-06-02 Sanofi-Aventis Combinaisons antitumorales contenant des anticorps reconnaissant spécifiquement les CD38 et cytarabine
MX2012004406A (es) * 2009-10-21 2012-05-08 Immunogen Inc Nuevo regimen de dosificacion y metodo de tratamiento.
EP2580243B1 (fr) 2010-06-09 2019-10-16 Genmab A/S Anticorps dirigés contre le cd38 humain
US8877899B2 (en) * 2010-09-27 2014-11-04 Morphosys Ag Anti-CD38 antibody and lenalidomide or bortezomib for the treatment of multipe myeloma and NHL
UA112170C2 (uk) * 2010-12-10 2016-08-10 Санофі Протипухлинна комбінація, що містить антитіло, яке специфічно розпізнає cd38, і бортезоміб
JOP20210044A1 (ar) 2010-12-30 2017-06-16 Takeda Pharmaceuticals Co الأجسام المضادة لـ cd38
HUE048876T2 (hu) 2011-05-09 2020-08-28 Mayo Found Medical Education & Res Rákos megbetegedések kezelése
CN104203982B (zh) 2011-10-28 2018-08-31 特瓦制药澳大利亚私人有限公司 多肽构建体及其用途
HRP20171964T1 (hr) 2012-09-25 2018-02-23 Morphosys Ag Kombinacije i njihova upotreba
US10413606B2 (en) 2012-10-01 2019-09-17 Mayo Foundation For Medical Education And Research Methods for treating cancer with nanoparticle complexes of albumin-bound paclitaxel and anti-VEGF antibodies
US10342869B2 (en) 2012-12-07 2019-07-09 The Regents Of The University Of California Compositions comprising anti-CD38 antibodies and lenalidomide
UA118255C2 (uk) * 2012-12-07 2018-12-26 Санофі Композиція, яка містить антитіло до cd38 і леналідомід
SG10201913777XA (en) * 2013-03-13 2020-03-30 Sanofi Sa Compositions comprising anti-cd38 antibodies and carfilzomib
CA2909952C (fr) * 2013-04-29 2021-10-12 Teva Pharmaceuticals Australia Pty Ltd. Anticorps anti-cd38 et fusions sur un interferon alpha-2b attenue
US9963515B2 (en) 2013-04-29 2018-05-08 Teva Pharmaceuticals Australia Pty Ltd. Anti-CD38 antibodies and fusions to attenuated interferon alpha-2B
MX373301B (es) * 2013-10-31 2020-04-24 Sanofi Sa Anticuerpos anti-cd38 específicos para usarse para tratar cánceres humanos.
US9603927B2 (en) 2014-02-28 2017-03-28 Janssen Biotech, Inc. Combination therapies with anti-CD38 antibodies
US9732154B2 (en) * 2014-02-28 2017-08-15 Janssen Biotech, Inc. Anti-CD38 antibodies for treatment of acute lymphoblastic leukemia
UA119352C2 (uk) 2014-05-01 2019-06-10 Тева Фармасьютикалз Острейліа Пті Лтд Комбінація леналідоміду або помалідоміду і конструкції анти-cd38 антитіло-атенуйований інтерферон альфа-2b та спосіб лікування суб'єкта, який має cd38-експресуючу пухлину
EP3154586B1 (fr) 2014-06-13 2020-05-27 Mayo Foundation for Medical Education and Research Traitement de lymphomes
US10213513B2 (en) * 2014-06-16 2019-02-26 Mayo Foundation For Medical Education And Research Treating myelomas
US10617757B2 (en) * 2014-08-08 2020-04-14 The Regents Of The University Of California Methods for treating multiple myeloma
WO2016040294A2 (fr) * 2014-09-09 2016-03-17 Janssen Biotech, Inc. Polythérapies avec des anticorps anti-cd38
CN107073132B (zh) 2014-10-06 2021-08-27 梅约医学教育与研究基金会 载体-抗体组合物及其制备和使用方法
PE20170908A1 (es) 2014-10-29 2017-07-12 Teva Pharmaceuticals Australia Pty Ltd VARIANTES DE INTERFERON a2b
PE20171094A1 (es) * 2014-12-04 2017-08-07 Janssen Biotech Inc Anticuerpos anti-cd38 para el tratamiento de la leucemia linfoblastica aguda
US10533057B2 (en) 2015-05-13 2020-01-14 Morphosys Ag Treatment for multiple myeloma (MM)
CR20170526A (es) * 2015-05-20 2018-04-03 Janssen Biotech Inc ANTICUERPOS ANTI-CD38 PARA EL TRATAMIENTO DE AMILOIDOSIS DE CADENA LIGERA y OTRAS ENFERMEDADES MALIGNAS HEMATOLÓGICAS POSITIVAS PARA CD38
JP6871919B2 (ja) 2015-06-16 2021-05-19 ナノファギックス エルエルシー 薬物送達及びイメージング化学コンジュゲート、製剤及びその使用方法
CN107708734B (zh) * 2015-06-22 2022-01-11 詹森生物科技公司 用抗cd38抗体和生存素抑制剂联合治疗血红素恶性肿瘤
US20170044265A1 (en) * 2015-06-24 2017-02-16 Janssen Biotech, Inc. Immune Modulation and Treatment of Solid Tumors with Antibodies that Specifically Bind CD38
EP3313441B1 (fr) * 2015-06-24 2024-02-21 Janssen Biotech, Inc. Modulation immunitaire et traitement de tumeurs solides avec des anticorps se liant spécifiquement à cd38
TW201707725A (zh) 2015-08-18 2017-03-01 美國馬友醫藥教育研究基金會 載體－抗體組合物及其製造及使用方法
TW201713360A (en) 2015-10-06 2017-04-16 Mayo Foundation Methods of treating cancer using compositions of antibodies and carrier proteins
JP7027321B2 (ja) * 2015-11-03 2022-03-01 ヤンセン バイオテツク，インコーポレーテツド 抗ｃｄ３８抗体の皮下製剤及びその使用
US10781261B2 (en) 2015-11-03 2020-09-22 Janssen Biotech, Inc. Subcutaneous formulations of anti-CD38 antibodies and their uses
WO2017120501A1 (fr) 2016-01-07 2017-07-13 Mayo Foundation For Medical Education And Research Procédés de traitement du cancer par interféron
US11351254B2 (en) 2016-02-12 2022-06-07 Mayo Foundation For Medical Education And Research Hematologic cancer treatments
EP3432928A4 (fr) 2016-03-21 2019-11-20 Mayo Foundation for Medical Education and Research Procédés d'amélioration de l'indice thérapeutique d'un médicament chimiothérapeutique
WO2017165440A1 (fr) 2016-03-21 2017-09-28 Mayo Foundation For Medical Education And Research Procédés de réduction de la toxicité d'un médicament chimiothérapeutique
US10618969B2 (en) 2016-04-06 2020-04-14 Mayo Foundation For Medical Education And Research Carrier-binding agent compositions and methods of making and using the same
WO2018002181A1 (fr) 2016-06-28 2018-01-04 Umc Utrecht Holding B.V. Traitement de maladies médiées par l'ige avec des anticorps qui se lient spécifiquement à cd38
MA45674A (fr) 2016-07-15 2019-05-22 Takeda Pharmaceuticals Co Méthodes et matériaux permettant d'évaluer une réponse à des traitements de déplétion de plasmoblastes et de plasmocytes
CN109843336A (zh) 2016-09-01 2019-06-04 梅约医学教育与研究基金会 用于靶向t细胞癌症的方法和组合物
CN109890419A (zh) 2016-09-01 2019-06-14 梅约医学教育与研究基金会 用于治疗癌症的载体-pd-l1结合剂组合物
US11590098B2 (en) 2016-09-06 2023-02-28 Mayo Foundation For Medical Education And Research Methods of treating triple-negative breast cancer using compositions of antibodies and carrier proteins
AU2017324947A1 (en) 2016-09-06 2019-03-28 Mayo Foundation For Medical Education And Research Paclitaxel-albumin-binding agent compositions and methods for using and making the same
CN109843924A (zh) 2016-09-06 2019-06-04 梅约医学教育与研究基金会 治疗表达pd-l1的癌症的方法
EP3544612A4 (fr) * 2016-11-23 2020-05-13 Acetylon Pharmaceuticals, Inc. Combinaisons pharmaceutiques comprenant un inhibiteur d'histone désacétylase et un inhibiteur de cd38 et leurs méthodes d'utilisation
EP3581190B1 (fr) 2016-12-09 2021-03-10 ONK Therapeutics Limited Cellules tueuses naturelles modifiées et leurs utilisations
BR112020002636A2 (pt) * 2017-08-10 2020-07-28 Grifols Diagnostic Solutions Inc. composições, métodos e/ou kits que compreendem um domínio extracelular recombinante de cd38 humano
WO2019035938A1 (fr) 2017-08-16 2019-02-21 Elstar Therapeutics, Inc. Molécules multispécifiques se liant à bcma et leurs utilisations
US11618787B2 (en) 2017-10-31 2023-04-04 Janssen Biotech, Inc. Methods of treating high risk multiple myeloma
MX2020007429A (es) 2018-01-12 2020-10-15 Takeda Pharmaceuticals Co Dosificacion subcutanea de anticuerpos anti grupo de diferenciacion 38 (cd38).
JP6648171B2 (ja) * 2018-02-02 2020-02-14 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗ｃｄ３８抗体及び弱毒化インターフェロンアルファ−２ｂとの融合物
WO2019220368A1 (fr) * 2018-05-16 2019-11-21 Janssen Biotech, Inc. Anticorps bispécifiques bcma/cd3 et gprdc5d/cd3 aux fins d'utilisation dans le traitement du cancer
EP3820900A1 (fr) 2018-07-13 2021-05-19 Genmab A/S Variants d'anticorps cd38 et leurs utilisations
MA53123A (fr) 2018-07-13 2021-05-19 Genmab As Thérapie à médiation par trogocytose utilisant des anticorps cd38
EP3860342A4 (fr) * 2018-10-03 2022-08-03 Prescient Pharma LLC Compositions et méthodes pour isoler des cellules circulantes
TWI924633B (zh) 2019-03-15 2026-05-11 德商莫菲西斯公司 用於治療自體抗體介導的自體免疫疾病的抗-cd38 抗體及其醫藥組成物
WO2020250033A1 (fr) 2019-06-10 2020-12-17 Takeda Pharmaceutical Company Limited Polythérapies utilisant des anticorps cd-38
GB201916150D0 (en) 2019-11-06 2019-12-18 Univ Of Ireland Galway Treatment of multiple myeloma
CN112876563B (zh) 2019-11-29 2022-08-16 康诺亚生物医药科技（成都）有限公司 药物组合物及其制备方法和应用
JP6853392B2 (ja) * 2020-01-15 2021-03-31 テバ・ファーマシューティカルズ・オーストラリア・ピーティワイ・リミテッド 抗ｃｄ３８抗体及び弱毒化インターフェロンアルファ−２ｂとの融合物
MX2022008050A (es) 2020-01-16 2022-07-27 Genmab As Formulaciones de anticuerpos anti cumulo de diferenciacion 38 (cd38) y usos de las mismas.
WO2021173844A1 (fr) 2020-02-26 2021-09-02 Biograph 55, Inc. Anticorps bispécifiques c19 c38
EP4121112A4 (fr) 2020-05-08 2023-11-15 The University Of Southern California Conjugués anticorps-médicament spécifiques au site par adp-ribosyl cyclases
KR20230079074A (ko) * 2020-09-01 2023-06-05 더 리전츠 오브 더 유니버시티 오브 캘리포니아 면역글로불린 ｅ 항체 조성물 및 사용 방법
EP4277930A1 (fr) 2021-01-14 2023-11-22 MorphoSys AG Anticorps anti-cd38 et leurs utilisations
TW202302642A (zh) 2021-03-01 2023-01-16 德商莫菲西斯公司 用於治療抗體介導移植物排斥用途之抗ｃｄ３８抗體
TW202321303A (zh) 2021-07-19 2023-06-01 德商莫菲西斯公司 抗pla2r自體抗體媒介膜性腎病變之治療
US20250382378A1 (en) 2022-10-31 2025-12-18 Genmab A/S Cd38 antibodies and uses thereof
TW202440636A (zh) 2023-03-21 2024-10-16 美商傳記５５有限公司 Ｃｄ１９／ｃｄ３８多特異性抗體

Family Cites Families (95)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5179017A (en) 1980-02-25 1993-01-12 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4399216A (en) 1980-02-25 1983-08-16 The Trustees Of Columbia University Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4634665A (en) 1980-02-25 1987-01-06 The Trustees Of Columbia University In The City Of New York Processes for inserting DNA into eucaryotic cells and for producing proteinaceous materials
US4376110A (en) 1980-08-04 1983-03-08 Hybritech, Incorporated Immunometric assays using monoclonal antibodies
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
JPS6147500A (ja) 1984-08-15 1986-03-07 Res Dev Corp Of Japan キメラモノクロ−ナル抗体及びその製造法
EP0173494A3 (fr) 1984-08-27 1987-11-25 The Board Of Trustees Of The Leland Stanford Junior University Récepteurs chimériques par liaison et expression de l'ADN
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
JPS61134325A (ja) 1984-12-04 1986-06-21 Teijin Ltd ハイブリツド抗体遺伝子の発現方法
US5618920A (en) * 1985-11-01 1997-04-08 Xoma Corporation Modular assembly of antibody genes, antibodies prepared thereby and use
DE3689123T2 (de) 1985-11-01 1994-03-03 Xoma Corp Modulare einheit von antikörpergenen, daraus hergestellte antikörper und verwendung.
GB8601597D0 (en) 1986-01-23 1986-02-26 Wilson R H Nucleotide sequences
US4954617A (en) 1986-07-07 1990-09-04 Trustees Of Dartmouth College Monoclonal antibodies to FC receptors for immunoglobulin G on human mononuclear phagocytes
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
GB8717430D0 (en) 1987-07-23 1987-08-26 Celltech Ltd Recombinant dna product
WO1989008114A1 (fr) 1988-02-25 1989-09-08 The General Hospital Corporation Procede de clonage par immunoselection rapide
GB8809129D0 (en) 1988-04-18 1988-05-18 Celltech Ltd Recombinant dna methods vectors and host cells
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9014932D0 (en) 1990-07-05 1990-08-22 Celltech Ltd Recombinant dna product and method
ES2139598T3 (es) 1990-07-10 2000-02-16 Medical Res Council Procedimientos para la produccion de miembros de parejas de union especifica.
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
AU658370B2 (en) 1990-07-13 1995-04-13 General Hospital Corporation, The CD53 cell surface antigen and use thereof
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
ES2246502T3 (es) 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5194594A (en) 1990-09-07 1993-03-16 Techniclone, Inc. Modified antibodies
DE69129154T2 (de) 1990-12-03 1998-08-20 Genentech, Inc., South San Francisco, Calif. Verfahren zur anreicherung von proteinvarianten mit geänderten bindungseigenschaften
DE69233697T2 (de) 1991-03-01 2008-01-24 Dyax Corp., Cambridge Verfahren zur Entwicklung von bindenden Mikroproteinen
PT100379B (pt) 1991-04-10 1999-01-29 Scripps Research Inst Bibliotecas de receptores heterodimericos usando fagomideos
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
WO1994004679A1 (fr) 1991-06-14 1994-03-03 Genentech, Inc. Procede pour fabriquer des anticorps humanises
EP0593592B1 (fr) 1991-07-08 1998-03-25 The University Of Massachusetts At Amherst Copolymere en masse segmentee a cristaux liquides thermotropiques
DE4122599C2 (de) 1991-07-08 1993-11-11 Deutsches Krebsforsch Phagemid zum Screenen von Antikörpern
JP3540315B2 (ja) 1991-09-23 2004-07-07 メディカル リサーチ カウンシル キメラ抗体の製造−組合せアプローチ
JPH05244982A (ja) 1991-12-06 1993-09-24 Sumitomo Chem Co Ltd 擬人化ｂ−ｂ１０
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
GB9223377D0 (en) 1992-11-04 1992-12-23 Medarex Inc Humanized antibodies to fc receptors for immunoglobulin on human mononuclear phagocytes
AU6123894A (en) 1993-01-29 1994-08-15 Board Of Trustees Of The Leland Stanford Junior University Modulation of physiological responses of lymphocytes by cd38 or antibodies thereto
AU693436B2 (en) 1993-03-09 1998-07-02 Genzyme Corporation Isolation of components of interest from milk
AU6819494A (en) 1993-04-26 1994-11-21 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
GB9424449D0 (en) 1994-12-02 1995-01-18 Wellcome Found Antibodies
JP4233608B2 (ja) 1996-10-15 2009-03-04 塩野義製薬株式会社 自己抗体測定方法
ES2191827T3 (es) 1996-10-17 2003-09-16 Immunomedics Inc Conjugado de toxina no antigenica y proteina de fusion de un sistema receptor de penetracion intracelular.
WO2000006194A2 (fr) 1997-02-05 2000-02-10 Biotransplant, Inc. Depletion de cellules responsables du rejet d'une greffe induit par des anticorps
ATE302217T1 (de) 1997-05-02 2005-09-15 Us Gov Health & Human Serv Immuntoxine, die ein onc protein enthalten, gegen bösartige zellen
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US6719977B1 (en) 1998-02-12 2004-04-13 The General Hospital Corporation Methods to potentiate cancer therapies
AU3456099A (en) 1998-03-31 1999-10-18 Geron Corporation Methods and compositions for eliciting an immune response to a telomerase antigen
AU770718B2 (en) * 1998-06-05 2004-02-26 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to CD38 to treat multiple myeloma
PT1974747E (pt) * 1998-08-11 2012-09-05 Biogen Idec Inc Terapias de combinação para linfomas de células b compreendendo a administração de anticorpo anti-cd20
US7223397B1 (en) 1999-01-07 2007-05-29 Research Development Foundation Potentiation of anti-CD38-Immunotoxin cytotoxicity
US20050037969A1 (en) * 1999-05-14 2005-02-17 Arbor Vita Corporation Molecular interactions in hematopoietic cells
CN1399645A (zh) 1999-07-29 2003-02-26 米德列斯公司 Her2/neu的人单克隆抗体
NZ517202A (en) 1999-08-24 2004-05-28 Medarex Inc Human CTLA-4 antibodies and their uses
EP1174440A1 (fr) 2000-07-19 2002-01-23 U-BISys B.V. Un épitope exprimé sélectivement sur la molécule humaine CD38 et détecté par un fragment d'un anticorps humain de forme scFv dérivé d'une librairie "phage display"
US20070042436A1 (en) 2000-10-17 2007-02-22 Lund Frances E CD38 modulated chemotaxis
US6955884B2 (en) 2000-10-17 2005-10-18 Trudeau Institute, Inc. Methods for identifying compounds that inhibit CD38 activity
WO2002042468A2 (fr) 2000-11-27 2002-05-30 Geron Corporation Vecteurs de glycosyltransferase pour traitement du cancer
DE60131456T2 (de) 2000-11-30 2008-07-10 Medarex, Inc., Milpitas Transchromosomale transgen-nagetiere zur herstellung von humanen antikörpern
US20030133939A1 (en) 2001-01-17 2003-07-17 Genecraft, Inc. Binding domain-immunoglobulin fusion proteins
US7754208B2 (en) 2001-01-17 2010-07-13 Trubion Pharmaceuticals, Inc. Binding domain-immunoglobulin fusion proteins
KR100945108B1 (ko) 2001-06-13 2010-03-02 젠맵 에이/에스 표피 성장 인자 수용체 (ｅｇｆｒ)에 대한 인간모노클로날 항체
US20040166490A1 (en) 2002-12-17 2004-08-26 Morris David W. Novel therapeutic targets in cancer
US20040019915A1 (en) * 2002-04-01 2004-01-29 Challita-Eid Pia M. Nucleic acid and corresponding protein entitled 213P1F11 useful in treatment and detection of cancer
EP1393720A1 (fr) 2002-08-27 2004-03-03 Universiteit Utrecht Vesicules encapsulant des corticosteroides pour le traitement du cancer
KR100944575B1 (ko) * 2002-10-17 2010-02-25 젠맵 에이/에스 Ｃｄ20에 대한 인간 모노클로날 항체
AU2003295471B2 (en) 2002-11-15 2011-08-25 Genmab A/S Human monoclonal antibodies against CD25
NZ541050A (en) 2002-12-16 2010-06-25 Genmab As Human monoclonal antibodies against interleukin 8 (IL-8)
JP4733635B2 (ja) * 2003-07-31 2011-07-27 イミューノメディクス、インコーポレイテッド 抗ｃｄ１９抗体
EP1689435A4 (fr) 2003-10-22 2007-10-03 Univ Rochester Antiserum anti-thymocyte et son utilisation pour declencher l'apoptose des cellules b
PT1684805E (pt) * 2003-11-04 2010-10-26 Novartis Vaccines & Diagnostic Utilização de anticorpos monoclonais antagonistas anti-cd40 para o tratamento do mieloma múltiplo
EA200600921A1 (ru) * 2003-11-06 2006-10-27 Селджин Корпорейшн Способы и композиции с применением талидомида для лечения и менеджмента рака и других заболеваний
MXPA06008700A (es) * 2004-02-06 2007-01-19 Morphosys Ag Anticuerpos anti-cd38 humanos y usos para los mismos.
EP2915820A1 (fr) 2004-02-06 2015-09-09 MorphoSys AG Anticorps humains anti-CD38 et utilisations de ceux-ci
US20050266008A1 (en) * 2004-03-29 2005-12-01 Medarex, Inc. Human anti-IRTA-5 antibodies
CN100416371C (zh) * 2004-04-21 2008-09-03 大日本印刷株式会社 彩色滤光片和具备该彩色滤光片的液晶显示装置
US20060019303A1 (en) * 2004-07-23 2006-01-26 Boehringer Ingelheim Pharmaceuticals, Inc. Method to identify and analyze genes having modified expression in stimulated T cells
EP2551282A3 (fr) 2005-03-23 2013-02-13 Genmab A/S Anticorps diriges contre CD38 pour le traitement du myelome multiple
TW200745162A (en) 2005-05-24 2007-12-16 Morphosys Ag Generation and profiling of fully human hucal gold-derived therapeutic antibodies specific for human CD38
PL2081595T3 (pl) * 2006-09-26 2019-11-29 Genmab As Anty-cd38 wraz z kortykosteroidami wraz ze środkiem chemioterapeutycznym niebędącym kortykosteroidem, do leczenia guzów nowotworowych
US20090076249A1 (en) * 2007-09-19 2009-03-19 Michel De Weers Antibodies against CD38 for treatment of multiple myeloma

Also Published As

Publication number Publication date
CY2021038I2 (el) 2023-11-15
LTPA2021015I1 (fr) 2022-01-25
CY2019036I1 (el) 2020-05-29
AU2013203186A1 (en) 2013-05-02
ES2732278T3 (es) 2019-11-21
LTPA2019515I1 (lt) 2019-10-25
LTPA2020520I1 (lt) 2020-07-27
FR20C1034I1 (fr) 2020-10-02
IL248204A0 (en) 2016-11-30
LTPA2025516I1 (fr) 2025-05-12
LUC00129I2 (fr) 2024-05-22
CY1121813T1 (el) 2020-05-29
JP2016188228A (ja) 2016-11-04
CY2019037I1 (el) 2020-05-29
US20200114000A1 (en) 2020-04-16
CY2019037I2 (el) 2020-05-29
TR201910145T4 (tr) 2019-08-21
AU2013203186B2 (en) 2016-06-16
HUS2500018I1 (hu) 2025-05-28
FR19C1056I1 (fr) 2019-11-15
EP3753576A1 (fr) 2020-12-23
LTPA2019516I1 (lt) 2019-10-25
CY2020016I1 (el) 2020-11-25
HUS1900044I1 (hu) 2019-11-28
CY2019035I1 (el) 2020-05-29
WO2008037257A2 (fr) 2008-04-03
JP6607825B2 (ja) 2019-11-20
FIC20250018I1 (fi) 2025-04-17
CY2021037I2 (el) 2022-03-24
IL197727A0 (en) 2011-08-01
FR19C1055I1 (fr) 2019-11-15
NZ576122A (en) 2012-09-28
LTPA2019514I1 (lt) 2025-12-29
CY2019035I2 (el) 2020-05-29
JP6907165B2 (ja) 2021-07-21
AU2007302448C1 (en) 2019-02-14
CY2019036I2 (el) 2020-05-29
HUS1900043I1 (hu) 2019-11-28
HUE044136T2 (hu) 2019-09-30
CY2021037I1 (el) 2022-03-24
ME03503B (fr) 2020-04-20
JP2021119198A (ja) 2021-08-12
PL2081595T3 (pl) 2019-11-29
FR21C1063I1 (fr) 2022-02-18
LUC50004I2 (fr) 2026-05-05
LUC50004I1 (fr) 2025-04-18
HRP20191115T1 (hr) 2019-09-20
JP2010504363A (ja) 2010-02-12
AU2013203186C1 (en) 2019-02-14
AU2007302448B2 (en) 2013-12-19
FR21C1062I1 (fr) 2022-02-18
CA2664740A1 (fr) 2008-04-03
SI2081595T1 (sl) 2019-10-30
US20150231235A1 (en) 2015-08-20
WO2008037257A3 (fr) 2008-06-05
JP2023120436A (ja) 2023-08-29
CY2025011I1 (el) 2026-02-25
FR25C1015I1 (fr) 2025-06-20
LUC00130I2 (fr) 2024-05-22
FR19C1057I1 (fr) 2019-11-15
US9040050B2 (en) 2015-05-26
EA034877B1 (ru) 2020-04-01
EP2081595A2 (fr) 2009-07-29
JP2025143484A (ja) 2025-10-01
CY2025011I2 (el) 2026-02-25
CY2021038I1 (el) 2022-03-24
HUS2100057I1 (hu) 2022-01-28
JP2014141492A (ja) 2014-08-07
EP3569245A1 (fr) 2019-11-20
LTPA2021014I1 (fr) 2022-01-10
US20240165226A1 (en) 2024-05-23
US20100092489A1 (en) 2010-04-15
RS59005B1 (sr) 2019-08-30
HUS2100056I1 (hu) 2022-01-28
IL197727A (en) 2017-01-31
EA200970317A1 (ru) 2009-10-30
HUS1900045I1 (hu) 2019-11-28
JP2019001804A (ja) 2019-01-10
CA2664740C (fr) 2021-11-16
JP5476122B2 (ja) 2014-04-23
AU2007302448A1 (en) 2008-04-03
LT2081595T (lt) 2019-07-10
CY2020016I2 (el) 2020-11-25
DK2081595T3 (da) 2019-07-15
PT2081595T (pt) 2019-07-16
EP2081595B1 (fr) 2019-04-10

Similar Documents

Publication Publication Date Title
BE2013C044I2 (fr)
CN300730944S (zh) Usb供电按摩器
CN300729720S (zh) 钧瓷(梅瓶)
CN300729011S (zh) 毛巾(卡通茶壶)
CN300729980S (zh) 变光开关
CN300731025S (zh) 头盔
CN300727388S (zh) 汽车侧围
CN300726189S (zh) 印花面料(花儿绽放二系列)
CN300725942S (zh) 童装(3874)
CN300726630S (zh) 炊具手柄(汽车长柄)
CN300727250S (zh) 项链(yh-0275)
CN300728182S (zh) 浴缸(2)
CN300727604S (zh) 电脑机箱面板(4712)
CN300732176S (zh) 毛巾被包装袋(二)
CN300731091S (zh) 拖鞋(3242)
CN300727434S (zh) 小型风力发电机组
CN300726050S (zh) 领带(“一摁得”名胜—富士山)
CN300729058S (zh) 餐具(5)
CN300731836S (zh) 管子钳(2)
CN300727829S (zh) 写字格纸
CN300726595S (zh) 咖啡壶(gc型)
CN300731202S (zh) 面料(zj-165)
CN300728144S (zh) 进水管组件(2)
CN300728282S (zh) 背景板(puy0145)
CN300729174S (zh) 砧板(4)